Azelaic Acid 12% | Hydroquinone 6% | Desonide 0.05%

Applied topically as a thin, even layer to affected hyperpigmented areas of the face or body per prescriber direction:

• Cleanse and dry the target area prior to application.
• Apply a thin layer and gently massage in until absorbed — do not rub vigorously.
• Avoid eyes, nostrils, mouth, and mucous membranes.
• Wash hands before and after application.
• Use broad-spectrum sunscreen (SPF 30+) daily, as hydroquinone and azelaic acid increase photosensitivity.

All dosing parameters are prescriber-determined. General use principles:

• Typically applied once or twice daily to affected areas as directed.
• Azelaic acid 12–15% is generally well-tolerated for twice-daily use; hydroquinone at 6% is typically restricted to once nightly or as directed due to higher irritation potential.
• Treatment courses are commonly 8–12 weeks, with prescriber re-evaluation at each interval.
• Strict photoprotection is required concurrently throughout treatment to prevent UV-driven repigmentation.

• Azelaic Acid: Competitively inhibits tyrosinase and reversibly inhibits mitochondrial oxidoreductases (including thioredoxin reductase) selectively in hyperactive melanocytes; also suppresses melanocyte proliferation and reduces reactive oxygen species driving melanogenesis. Does not depigment normally pigmented skin, providing a safety advantage in mixed-pigmentation presentations.
• Hydroquinone: Competitively inhibits tyrosinase, blocking the oxidation of DOPA to dopaquinone; secondarily degrades melanosomes, inhibits melanocyte DNA/RNA synthesis, and at 6% may exert direct melanocytotoxic effects.
• Desonide: Binds glucocorticoid receptors in melanocytes and keratinocytes, suppressing pro-inflammatory cytokine production (IL-1α, TNF-α), reducing tyrosinase gene transcription driven by inflammation, and attenuating irritant reactions to the other active agents.

This triple combination is prescribed for the prescriber-directed management of melasma, post-inflammatory hyperpigmentation (PIH), and hyperpigmented acne sequelae. Key clinical considerations:

• Azelaic acid's selective activity on abnormal melanocytes provides an additional safety margin compared with hydroquinone alone; the combination offers dual-mechanism attack on melanogenesis.
• Monitor for exogenous ochronosis (paradoxical blue-black darkening) with prolonged 6% hydroquinone use; document treatment duration and schedule prescriber evaluation every 8–12 weeks.
• Desonide 0.05% is a low-potency corticosteroid generally considered safe for facial use; however, continuous long-term application should be avoided to prevent skin atrophy.
• Azelaic acid 12–15% is established for acne and rosacea (FDA-approved at 15% and 20%); the 12% compounded strength is used off-label for hyperpigmentation management.
• Recommend monthly follow-up during active treatment; reinforce strict daily photoprotection as an essential adjunct.

Contraindications:

• Hypersensitivity to azelaic acid, hydroquinone, desonide, or any formulation component.
• Viral, fungal, or bacterial skin infection at the application site.
• Rosacea with pustular or telangiectatic features (corticosteroid component may exacerbate).

Warnings & Precautions:

• Exogenous ochronosis risk with prolonged 6% hydroquinone use; limit continuous duration per prescriber guidance.
• Avoid extended uninterrupted facial corticosteroid use; monitor for atrophy, telangiectasia, and perioral dermatitis.
• Azelaic acid may cause transient stinging, burning, or pruritus, especially during the first weeks of use.
• Avoid contact with eyes, nostrils, lips, and mucous membranes.

Drug Interactions:

• Concurrent retinoids or other keratolytics may increase irritation; use with caution and under prescriber guidance.

Common Side Effects: Stinging, burning, pruritus, and erythema at the application site (predominantly azelaic acid); skin lightening of affected areas; application site dryness.

Store at controlled room temperature (15–25°C / 59–77°F) in the original opaque container. Protect from heat, light, and humidity. Do not freeze. Keep out of reach of children. Use by the beyond-use date (BUD) assigned per USP <795> guidelines. Discard if color change, separation, or unusual odor develops.

How does this differ from azelaic acid alone?

This combination adds hydroquinone, the most potent available tyrosinase inhibitor, and desonide to control inflammation-driven pigmentation. The dual depigmenting mechanism (azelaic acid plus hydroquinone) may address both hyperactive melanocyte proliferation and enzymatic melanin synthesis simultaneously, while desonide limits irritation.

Why is desonide included?

Desonide is a low-potency corticosteroid that suppresses the inflammatory cascade driving post-inflammatory hyperpigmentation, reduces tyrosinase transcription in melanocytes, and helps the skin tolerate the combined irritant potential of hydroquinone and azelaic acid.

Is this preparation FDA-approved?

No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding. It is not FDA-approved as a finished drug product.

Do I need to wear sunscreen while using this?

Yes. Daily broad-spectrum sunscreen (SPF 30 or higher) is essential. UV exposure can re-activate melanogenesis and reverse therapeutic gains; without rigorous photoprotection, treatment response will be significantly compromised.

How long does treatment take?

Visible improvement typically requires 8–12 weeks of consistent use. Prescriber follow-up at 4–8 week intervals allows assessment of response, tolerability, and need for dose adjustment or maintenance therapy.